【HSBC Qianhai Securities Limited】【202603】Wuxi Biologics (2269 HK) - Buy Lifting three-year growth outlook, driven by accelerating CMO and IP-based revenue-10页

HSBC Qianhai Securities Limited 卫生和社会工作 2026年 PDF 5.8 MB

估值分析 制造业 业绩增长 生物医药 投资建议